Use of oligosaccharides for neutralising e. coli toxins

Details Use of oligosaccharides for neutralising e. coli toxins Use of oligosaccharides for neutralising e. coli toxins

A - Human Necessities

61

K

A61K 47/48 (2006.01)

Patent

CA 2243118

This invention is directed to the surprising and unexpected discovery that the clinical incidence of HUS arising from enterohemorrhagic E. coli infection is significantly reduced by the time critical administration of a pharmaceutical composition comprising a pharmaceutically inert affinity support comprising an .alpha.Gal(14).beta.Gal subunit which subunit binds the SLT. Specifically, it has been found that the clinical incidence of HUS arising from enterohemorrhagic E. coli infection is reduced when this pharmaceutical composition is administered within 3 days of presentation of the infection. Contrarily, administration of this pharmaceutical composition after this time frame or when organs other than the intestine are involved in the infection, substantially reduces the ability of this composition to reduce the incidence of HUS.

L'invention repose sur une découverte surprenante et inattendue selon laquelle l'incidence clinique du syndrome hémolytique et urémique (SHU) consécutive à une infection entérohémorrhagique par E. Coli peut se trouver notablement réduite par l'administration en temps voulu d'une préparation pharmaceutique comprenant un support à affinité pharmaceutique inerte comportant une sous unité .alpha.Gal(1>4).beta.Gal se fixant aux toxines de type Shiga (SLT). On a en particulier découvert que l'incidence clinique du SHU consécutive à une infection entérohémorrhagique par le E. Coli se trouvait réduite lorsque ladite préparation pharmaceutique était administrée dans les trois jours suivant l'apparition de l'infection. Par contre, l'administration de ladite préparation pharmaceutique après cette période ou lorsque d'autres organes que l'intestin sont touchés par l'infection en réduit sensiblement la capacité à réduire l'incidence du SHU.

Affiliated with

Also associated with

Rating

Use of oligosaccharides for neutralising e. coli toxins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of oligosaccharides for neutralising e. coli toxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of oligosaccharides for neutralising e. coli toxins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1698008